{"transactions":[{"id":4103,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & COO"}}],"security":"Restricted Stock Units","published_at":"2026-09-04T10:00:25.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":56000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant."}],"balance_after":56000,"derivative":{"underlying":"Common Stock","underlying_shares":56000},"source":{"system":"sec-edgar","filing":"0001742727-26-000002","document":"form4-09042026_060917.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1742727/000174272726000002/form4-09042026_060917.xml","form_type":"4"}},{"id":4102,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP & COO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-04T10:00:25.000Z","date":"2026-09-03","kind":"grant","planned":false,"acquired":true,"shares":112000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (ii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iv) options to purchase 100,000 shares of common stock at an exercise price equal to $1.10 per share that expire on September 23, 2034, and (v) options to purchase 50,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035."}],"balance_after":112000,"derivative":{"exercise_price":2.59,"expiration_date":"2036-09-03","underlying":"Common Stock","underlying_shares":112000},"source":{"system":"sec-edgar","filing":"0001742727-26-000002","document":"form4-09042026_060917.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1742727/000174272726000002/form4-09042026_060917.xml","form_type":"4"}},{"id":1048604,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-04T21:00:11.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Does not include (i) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (ii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 (iii) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iv) options to purchase 100,000 shares of common stock at an exercise price equal to $1.10 per share that expire on September 23, 2034."}],"balance_after":50000,"derivative":{"exercise_price":1.64,"expiration_date":"2035-09-03","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-023701","document":"form4-09042025_050903.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023701/form4-09042025_050903.xml","form_type":"4"}},{"id":1048603,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Operations"}}],"security":"Common Stock","published_at":"2025-09-04T21:00:11.000Z","date":"2025-09-03","kind":"grant","planned":false,"acquired":true,"shares":25000,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the \"Plan\"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant and are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":225817,"source":{"system":"sec-edgar","filing":"0001415889-25-023701","document":"form4-09042025_050903.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588925023701/form4-09042025_050903.xml","form_type":"4"}},{"id":1400488,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Operations"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-24T21:00:07.000Z","date":"2024-09-23","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 5,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025, (ii) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028, (iii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030 and (iv) options to purchase 340,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032."}],"balance_after":100000,"derivative":{"exercise_price":1.1,"expiration_date":"2034-09-23","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001415889-24-023906","document":"form4-09242024_050902.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000141588924023906/form4-09242024_050902.xml","form_type":"4"}},{"id":1804390,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Operations"}}],"security":"Common Stock","published_at":"2023-08-17T20:30:12.000Z","date":"2023-08-15","kind":"grant","planned":false,"acquired":true,"shares":187344,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the employee under its Amended and Restated 2006 Stock Incentive Plan, as amended. The shares vest over a three-year period beginning on the date of grant in 12 equal increments on each quarterly anniversary of the date of grant. The restricted shares are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Plan."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee."}],"balance_after":200817,"source":{"system":"sec-edgar","filing":"0001104659-23-093066","document":"tm2324046-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465923093066/tm2324046-1_4seq1.xml","form_type":"4"}},{"id":2162620,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Operations"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-09-09T21:04:21.000Z","date":"2022-09-07","kind":"grant","acquired":true,"shares":340000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 5,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025, (ii) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028 and (iii) options to purchase 122,656 shares of common stock at an exercise price equal to $3.59 per share that expire on August 11, 2030."}],"balance_after":340000,"derivative":{"exercise_price":1.03,"expiration_date":"2032-09-07","underlying":"Common Stock","underlying_shares":340000},"source":{"system":"sec-edgar","filing":"0001104659-22-098953","document":"tm2225460-9_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465922098953/tm2225460-9_4seq1.xml","form_type":"4"}},{"id":3059111,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Operations"}}],"security":"Stock Options (Right to Buy)","published_at":"2020-08-13T21:01:36.000Z","date":"2020-08-11","kind":"grant","acquired":true,"shares":122656,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant.  The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 5,000 shares of common stock at an exercise price equal to $17.20 per share that expire on March 23, 2025 and (ii) options to purchase 60,000 shares of common stock at an exercise price equal to $5.60 per share that expire on September 13, 2028."}],"balance_after":122656,"derivative":{"exercise_price":3.59,"expiration_date":"2030-08-11","underlying":"Common Stock","underlying_shares":122656},"source":{"system":"sec-edgar","filing":"0001104659-20-094751","document":"tm2027548d1_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465920094751/tm2027548d1_4.xml","form_type":"4"}},{"id":3816208,"issuer":{"id":2671,"kind":"organization","name":"Protalix BioTherapeutics, Inc.","symbol":"PLX"},"owners":[{"id":2677,"kind":"person","name":"Naos Yaron","position":1,"cik":"0001742727","reported_name":"Naos Yaron","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. VP, Operations"}}],"security":"Stock Options (Right to Buy)","published_at":"2018-09-14T20:30:59.000Z","date":"2018-09-13","kind":"grant","acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Does not include (i) options to purchase 50,000 shares of common stock at an exercise price equal to $2.65 per share that expire on February 25, 2019; (ii) options to purchase 115,000 shares of common stock at an exercise price equal to $6.90 per share that expire on February 25, 2020; and (iii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.72 per share that expire on March 23, 2025."}],"balance_after":600000,"derivative":{"exercise_price":0.56,"expiration_date":"2028-09-13","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001144204-18-049521","document":"tv502882_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1006281/000114420418049521/tv502882_4.xml","form_type":"4"}}]}